---
document_datetime: 2025-04-15 16:26:05
document_pages: 10
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/inlyta-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: inlyta-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 7.7070307
conversion_datetime: 2025-12-14 23:21:50.737629
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## Inlyta

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, please also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                   | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IA /  | This was an application for a variation | 07/03/2025                          | N/A                                         |                                  |           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000237698                        | following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. A. ADMINISTRATIVE CHANGES - A.4 Change in the name and/or address of: a manufacturer (including where relevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, starting material, reagent or intermediate used in the manufacture of the active substance (where specified in the technical dossier) where no Ph. Eur. Certificate of Suitability is part of the approved dossier; or a manufacturer of a novel excipient (where specified in the technical dossier) - Accepted   |            |            |                       |                                   |
|------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|-----------------------------------|
| Variation type IA_IN / EMA/VR/0000245212 | A.5 Change in the name and/or address of a manufacturer/importer of the finished product (including batch release or quality control testing sites) - A.5.a The activities for which the manufacturer/importer is responsible include batch release - Accepted                                                                                                                                                                                                                                                                                                                                                                    | 21/01/2025 |            | SmPC, Annex II and PL |                                   |
| PSUSA/10022/202201                       | Periodic Safety Update EU Single assessment - axitinib                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 29/09/2022 | n/a        |                       | PRAC Recommendation - maintenance |
| IA/0032                                  | A.6 - Administrative change - Change in ATC Code/ATC Vet Code                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 20/08/2021 | 21/09/2022 | SmPC and PL           |                                   |
| IA/0031                                  | B.II.b.2.a - Change to importer, batch release arrangements and quality control                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 05/05/2021 | n/a        |                       |                                   |

<div style=\"page-break-after: always\"></div>

|                    | testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                                                                                   |            |            |                                  |                                                                                                                                            |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0030            | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient | 20/11/2020 | n/a        |                                  |                                                                                                                                            |
| IB/0029            | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                               | 29/10/2020 |            | SmPC and PL                      |                                                                                                                                            |
| PSUSA/10022/201901 | Periodic Safety Update EU Single assessment - axitinib                                                                                                                                                                                       | 19/09/2019 | 11/11/2019 | SmPC and PL                      | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10022/201901. |
| IAIN/0028          | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                               | 31/10/2019 | 09/12/2020 | SmPC, Annex II, Labelling and PL |                                                                                                                                            |
| IG/1124            | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient | 11/09/2019 | n/a        |                                  |                                                                                                                                            |
| IB/0025            | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing                                                                                                                                                   | 22/05/2019 | n/a        |                                  |                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

|                    | authorisation, including the RMP - Other variation                                                                                                                    |            |            |                                  |                                                                                                                                                                                                                                                                      |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10022/201801 | Periodic Safety Update EU Single assessment - axitinib                                                                                                                | 20/09/2018 | 22/11/2018 | SmPC and PL                      | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10022/201801.                                                                                                                           |
| T/0024             | Transfer of Marketing Authorisation                                                                                                                                   | 11/07/2018 | 03/08/2018 | SmPC, Labelling and PL           |                                                                                                                                                                                                                                                                      |
| PSUSA/10022/201701 | Periodic Safety Update EU Single assessment - axitinib                                                                                                                | 01/09/2017 | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                    |
| R/0021             | Renewal of the marketing authorisation.                                                                                                                               | 23/03/2017 | 22/05/2017 | SmPC, Annex II, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Inlyta in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| PSUSA/10022/201601 | Periodic Safety Update EU Single assessment - axitinib                                                                                                                | 02/09/2016 | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                    |
| IAIN/0020          | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                        | 09/06/2016 | 22/05/2017 | SmPC and PL                      |                                                                                                                                                                                                                                                                      |
| IA/0018            | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate | 20/04/2016 | n/a        |                                  |                                                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

|           | used in the manufacture of the AS or manufacturer of a novel excipient                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |            |     |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IB/0017/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer | 04/04/2016 | n/a |

<div style=\"page-break-after: always\"></div>

|                    | limits applied during the manufacture of the AS - Other variation B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)   |            |            |             |                                   |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------|
| PSUSA/10022/201501 | Periodic Safety Update EU Single assessment - axitinib                                                                                                                                                                                                                                 | 10/09/2015 | n/a        |             | PRAC Recommendation - maintenance |
| N/0014             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                       | 24/06/2015 | 11/05/2016 | PL          |                                   |
| II/0013            | Update of sections 4.4 and 4.8 of the SmPC and relevant section of the Package Leaflet following a safety update of the Core Data Sheet. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                             | 21/05/2015 | 11/05/2016 | SmPC and PL |                                   |
| IB/0012/G          | This was an application for a group of variations. C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation C.I.11.z - Introduction of, or change(s) to,                                          | 27/03/2015 | n/a        |             |                                   |

<div style=\"page-break-after: always\"></div>

|                    | the obligations and conditions of a marketing authorisation, including the RMP - Other variation C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                      |            |            |      |                                                                                               |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|-----------------------------------------------------------------------------------------------|
| II/0011            | Submission of an update of the proposed research plan with an extensive summary of ongoing research for predictive anti- angiogenic biomarkers in advanced RCC published in the scientific literature in order to provide information on this matter. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority | 26/02/2015 | n/a        |      |                                                                                               |
| PSUSA/10022/201407 | Periodic Safety Update EU Single assessment - axitinib                                                                                                                                                                                                                                                                                                                                              | 12/02/2015 | n/a        |      | PRAC Recommendation - maintenance                                                             |
| PSUV/0009          | Periodic Safety Update                                                                                                                                                                                                                                                                                                                                                                              | 11/09/2014 | n/a        |      | PRAC Recommendation - maintenance                                                             |
| II/0006            | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                                       | 26/06/2014 | n/a        |      |                                                                                               |
| II/0008            | Update of section 4.5 of the SmPC to delete the information on CYP1A2 induction by                                                                                                                                                                                                                                                                                                                  | 22/05/2014 | 07/11/2014 | SmPC | An analysis on pooled pharmacokinetic data from total 210 subject was performed. Among these, |

<div style=\"page-break-after: always\"></div>

|         | smoking further results of a population pharmacokinetic modelling analysis of the evaluation of the effect of smoking on axitinib pharmacokinetics. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                          |            |            |             | there were 83 (39.5 %) current smokers and 56 (26.7 %) ex-smokers. The analysis did not indicate any clinically significant effect of smoking on the pharmacokinetics of axitinib. Thus, based on the currently available evidence, the CHMP agreed that it is not justified to recommend any dose modifications for axinitib in patients who are smokers.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0007 | Update of sections 4.4 and 4.8 of the SmPC in order to add \"cardiac failure events\" as a new adverse drug reaction reported with a frequency 'common' following a routine review of the MAH's safety database. The Package Leaflet is proposed to be updated accordingly. The MAH also took the opportunity to make minor editorial changes to the SmPC and Package leaflet. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 22/05/2014 | 07/11/2014 | SmPC and PL | In a controlled clinical study with axitinib (N = 359) for the treatment of patients with RCC, cardiac failure events were reported in 1.7 %patients receiving axitinib, including cardiac failure (0.6%), cardiopulmonary failure (0.6%), left ventricular dysfunction (0.3%), and right ventricular failure (0.3%). Grade 4 cardiac failure adverse reactions were reported in 0.6 %of patients receiving axitinib. Fatal cardiac failure was reported in 0.6 %of patients receiving axitinib. In monotherapy studies with axitinib (N = 672) for the treatment of patients with RCC, cardiac failure events (including cardiac failure, cardiac failure congestive, cardiopulmonary failure, left ventricular dysfunction, ejection fraction decreased, and right ventricular failure) were reported in 1.8% patients receiving axitinib. Grade 3/4 cardiac failure events were reported in 1.0% patients and fatal cardiac failure events were reported in 0.3% patients receiving axitinib. Signs or symptoms of cardiac failure should periodically be monitored throughout treatment with axitinib. Management of cardiac failure events may |

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |            |            |             | require temporary interruption or permanent discontinuation and/or dose reduction of axitinib therapy.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUV/0005 | Periodic Safety Update                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 06/03/2014 | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| II/0003/G | This was an application for a group of variations. Update of section 4.8 of the SmPC in order to include glossodynia as an adverse reaction. In addition section 4.8 of the SmPC has been updated with the frequencies of the adverse drug reactions as it was requested by the CHMP further to the assessment of the PSUR 1. The MAH took also the opportunity to make minor changes in section 4.8 based on the post marketing experience. Finally the MAH made one minor change in section 4.2 of the SmPC. The Package Leaflet was updated accordingly. C.I.3.b - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under Article 45/46, or amendments to reflect a Core SPC - Change(s) with new additional data submitted by the MAH C.I.4 - Variations related to significant | 24/10/2013 | 07/11/2014 | SmPC and PL | Based on the post-marketing data and the known association of glossodynia to other VEGFR inhibitors, a causal relationship to axitinib is at least a reasonable possibility, and therefore section 4.8 of the SmPC was updated to include it. Following the CHMP recommendation further to the assessment of the PSUR 1, the frequencies of the adverse drug reactions (ADRs) in the section of 4.8 of the SmPC were updated to reflect the new safety data cut-off date (1 June 2012) and reported according to treatment emergent, all-causality frequency. The MAH took also the opportunity to consolidate the ADRs included under 'Gastrointestinal perforation and fistula' in section 4.8 of the SmPC in order to improve the readability of the adverse drug reactions table and to align adverse drug reaction terms used in the Core Data Sheet (CDS) and SmPC, to add the ADR 'hyperbilirubinaemina' and to delete the ADR 'blood bilirubin increased'. Finally, the MAH made a minor change in section 4.2 of the SmPC in order to provide a more balanced phrasing and clarify the optional nature of the dose titration. |

<div style=\"page-break-after: always\"></div>

|           | new quality, pre-clinical, clinical or pharmacovigilance data                                                                                                                                                                                                                    |            |            |                                  |                                                                                                                                                                                                                                                                                                                                                                          |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| X/0001    | Annex I_2.(c) Change or addition of a new strength/potency                                                                                                                                                                                                                       | 27/06/2013 | 26/08/2013 | SmPC, Annex II, Labelling and PL | This line extension introduces two additional tablet strengths 3mg and 7 mg of axitinib in addition to the currently approved 1mg and 5 mg tablets. The proposed maximum clinical dose is 10 mg twice daily. The two additional strengths are intended to simplify dosing for patients who need dose modification up or down from the starting dose of 5 mg twice daily. |
| N/0004    | The MAH applied to include the contact details for Croatia to the list of local representatives. Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                | 04/07/2013 | 22/05/2017 | PL                               |                                                                                                                                                                                                                                                                                                                                                                          |
| IG/0235/G | This was an application for a group of variations. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation C.I.9.b - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the contact details of the QPPV | 06/12/2012 | n/a        |                                  | C.I.z - To replace the Detailed Description of the Pharmacovigilance System (DDPS) with the Pharmacovigilance System Master File (PSMF).                                                                                                                                                                                                                                 |